Baxter Confirms Receipt of Complete Response Letter on HyQ
16:01 EDT 1 Aug 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Baxter International Inc. (NYSE:BAX) today announced that the U.S. Food
and Drug Administration (FDA) has issued a complete response letter for
HyQ, an investigational combination immunoglobulin product for the
treatment of pati...
Other Sources for this Article
Baxter International Inc.
Media Contacts
Deborah Spak,
224-948-2349
Brian Kyhos, 224-948-4210
or
Investor
Contacts
Mary Kay Ladone, 224-948-3371
Clare Trachtman,
224-948-3085
More From BioPortfolio on "Baxter Confirms Receipt of Complete Response Letter on HyQ"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
